12.03.15
Zealand Pharma has named Carlos de Sousa as senior vice president, chief business officer. Mr. de Sousa brings extensive experience and a vast contact network from numerous senior management positions in the international pharmaceutical and biotech industries, including roles at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics and Newron Pharmaceuticals.
Throughout his career, he has worked extensively with business development including in-licensing, partnering, mergers and acquisition, corporate leadership, strategy, marketing and medical affairs.
"I and the rest of senior management are pleased to welcome Carlos de Sousa to Zealand,” said Britt Meelby Jensen, president and chief executive officer, Zealand. “He is a highly experienced executive with a strong international track record and a broad range of competencies to complement our team. We have recently outlined Zealand's strategic path towards accelerated value creation from Peptide to Patient with a focus on expanding and advancing our scientific expertise and proprietary pipeline of specialty medicines. An important element is to strengthen our business through external innovation and collaborative partnerships, and I am confident that Carlos will add significant value as we execute on our strategy."
Throughout his career, he has worked extensively with business development including in-licensing, partnering, mergers and acquisition, corporate leadership, strategy, marketing and medical affairs.
"I and the rest of senior management are pleased to welcome Carlos de Sousa to Zealand,” said Britt Meelby Jensen, president and chief executive officer, Zealand. “He is a highly experienced executive with a strong international track record and a broad range of competencies to complement our team. We have recently outlined Zealand's strategic path towards accelerated value creation from Peptide to Patient with a focus on expanding and advancing our scientific expertise and proprietary pipeline of specialty medicines. An important element is to strengthen our business through external innovation and collaborative partnerships, and I am confident that Carlos will add significant value as we execute on our strategy."